<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04518813</url>
  </required_header>
  <id_info>
    <org_study_id>RSP-24</org_study_id>
    <nct_id>NCT04518813</nct_id>
  </id_info>
  <brief_title>A Study of a Non-invasive Glucose Measuring Device in Out-patient Settings</brief_title>
  <official_title>An Explorative Study of a Novel Non-invasive Glucose Measuring Device in Out-patient Settings</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RSP Systems A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RSP Systems A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This explorative clinical investigation has been launched to collect spectral Raman data&#xD;
      paired with validated glucose reference values in persons with diabetes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 24, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of number of calibration days</measure>
    <time_frame>2 years</time_frame>
    <description>The number of calibration days needed for reaching a well-performing glucose predictive calibration model will be determined. The clinical performance of the reduced calibration model will be based on the data from the validation part by studying linear regression, Inter Subject Unified Performance value and Consensus Error Grid.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety evaluation of the Investigational Medical Device by reporting of adverse events</measure>
    <time_frame>2 years</time_frame>
    <description>Safety of the IMD will be evaluated in a descriptive manner by the paucity of adverse events reported during the clinical investigation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device function</measure>
    <time_frame>2 years</time_frame>
    <description>Device function will be evaluated in regard to durability and reliability. This is evaluated by reported device deficiencies during the study in the terms of subject diaries</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">182</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>RSP-24</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will perform calibrations on the IMD (Prototype 0.5) for 41 days over a 60 day period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Prototype 0.5</intervention_name>
    <description>Investigational Medical Device collecting Raman data from tissue</description>
    <arm_group_label>RSP-24</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female subjects minimum 18 years of age&#xD;
&#xD;
          -  Individuals diagnosed with any type of insulin-dependent diabetes mellitus ≥ 1 year&#xD;
&#xD;
          -  Willing to perform up to 12 finger-pricks during each day of out-patient measurements&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  For women of childbearing potential: Willing and able to practice FDA approved birth&#xD;
             control during the duration of the investigation&#xD;
&#xD;
          -  Subject has a 2.4 GHz wireless internet connection at home (standard in normal&#xD;
             routers) to be used in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  For female subjects: Pregnancy or breastfeeding&#xD;
&#xD;
          -  Skin phototype VI categorized by Fitzpatrick scale measured on thenar&#xD;
&#xD;
          -  Subjects not able to understand and read local language&#xD;
&#xD;
          -  Cognitive impairment, or in investigator's opinion, subject is not able to follow&#xD;
             instructions provided and as specified in the protocol&#xD;
&#xD;
          -  Subject not able to hold hand/arm steady (including tremors and Parkinson's Disease)&#xD;
&#xD;
          -  Extensive skin changes, tattoos or diseases on right thenar (measurement site)&#xD;
&#xD;
          -  Reduced circulation in right hand evaluated by Allen's test&#xD;
&#xD;
          -  Known allergy to medical grade alcohol&#xD;
&#xD;
          -  Hemodialysis&#xD;
&#xD;
          -  Systemic or topical administration of glucocorticoids at the right hand for the past 7&#xD;
             days or during the study period expected&#xD;
&#xD;
          -  Any disorder, which in the investigator's opinion might jeopardize subject's safety or&#xD;
             compliance with the protocol&#xD;
&#xD;
          -  Severe diabetes-related complications such as advanced autonomic neuropathy, kidney&#xD;
             disease, foot ulcers, legal blindness, or symptomatic cardiovascular disease as&#xD;
             evidenced by a history of cardiovascular episode(s)&#xD;
&#xD;
          -  Dependency from the sponsor or the clinical investigator (e.g. co-workers of the&#xD;
             sponsor, the study site, and/ or their families)&#xD;
&#xD;
          -  Subjects currently participating in another study&#xD;
&#xD;
          -  Subjects who have participated in the study IDT-1904-RO/RSP-21 or RSP-19.&#xD;
&#xD;
          -  Incapacity for consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mette Riis Jensen</last_name>
    <phone>+45 40362854</phone>
    <email>mettej@rspsystems.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut für Diabetes-Technologie, Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guido Freckmann, MD</last_name>
      <phone>+49 (0) 731-50 990 16</phone>
      <email>guido.freckmann@idt-ulm.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>August 13, 2020</study_first_submitted>
  <study_first_submitted_qc>August 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2020</study_first_posted>
  <last_update_submitted>October 6, 2020</last_update_submitted>
  <last_update_submitted_qc>October 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-invasive glucose monitoring</keyword>
  <keyword>Raman spectroscopy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

